Protective effects of antibodies against Neisseria meningitidis serogroups A, C, W135 and Y in healthy children under 14 years of age in Jiangsu province
WU Yun, CHEN Qiang, LENG Hong-ying
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu 210009, China
Abstract：Objective To investigate the immune status of population and evaluate the vaccination effect by detecting antibodies against Neisseria meningitides (N. meningitidis) serogroups A, C, W135 and Y in healthy children in Jiangsu province. Methods A stratified random sampling method was used to select 517 healthy children younger than 14 years in Huai’an and Yancheng. Indirect enzyme-linked immunosorbent assay (ELISA) was employed to detect polysaccharide immunoglobulin G (IgG) antibodies against N. meningitidis serogroups A, C, W135 and Y. SPSS 20.0 software was used for statistical analysis. Results The percentages of healthy children with IgG concentration achieved the protective level of 2 μg/ml against N. meningitidis serogroups A, C, W135 and Y were 76.02%, 65.38%, 29.21% and 45.26%, respectively, and the geometric mean concentration (GMC) of IgG antibodies against N. meningitidis serogroups A, C, W135 and Y was 4.59 μg/ml, 2.90 μg/ml, 1.06 μg/ml and 1.55 μg/ml, respectively. There were statistically significant differences in the concentration of IgG antibodies against N. meningitidis serogroups A and C among different age groups (F=14.118, F=32.008;P<0.05) as well as in the percentages of participants with IgG concentration ≥2 μg/ml against serogroups A and C (χ2=31.745, χ2=41.354; P<0.05). The antibody GMC and the percentages of protective antibodies were found to be the highest in the age group of 6- years.Among the groups with different ages,no statistically significant differences were found in the concentration of IgG antibodies against N. meningitidis serogroups W135 and Y(F=2.558, F=0.611; P>0.05)as well as in the percentages ofhealthy childrenwith IgG concentration ≥2 μg/ml against serogroups W135 and Y (χ2=0.800, χ2=1.896; P>0.05). Among the groups with different immunization histories, there were statistically significant differences in the concentration of IgG antibodies against N. meningitidis serogroups A and C (F=11.021, F=22.421; P<0.05) as well as in the percentages of healthy children with IgG concentration ≥2 μg/ml against serogroups A and C (χ2=41.578, χ2=46.300; P<0.05), and all the above-mentioned indexes increased with the times of immunization. Conclusions Current vaccination of meningococcal vaccine in China can provide a certain degree of immune protection against N. meningitidis serogroups A and C, but the intensity of immune response and immune persistence are still insufficient. It is recommended to continue to improve the immune efficacy and expand the coverage of meningococcal vaccine against serogroups A, C, W135 and Y, and simultaneously further adjust immune strategy to prevent the epidemic spread of Neisseria meningitidis.
吴昀, 陈强, 冷红英. 江苏省14岁以下健康儿童脑膜炎奈瑟菌A、C、W135、Y群抗体水平保护性分析[J]. 实用预防医学, 2019, 26(12): 1458-1461.
WU Yun, CHEN Qiang, LENG Hong-ying. Protective effects of antibodies against Neisseria meningitidis serogroups A, C, W135 and Y in healthy children under 14 years of age in Jiangsu province. , 2019, 26(12): 1458-1461.
[1] van Kessel F, van den Ende C, Oordt-Speets AM, et al. Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review[J]. J Glob Health, 2019, 9(1):010411. [2] Baker CJ. Prevention of meningococcal infection in the United States: current recommendations and future considerations[J]. J Adolesc Health,2016, 59(2 Suppl):S29-37. [3] 中华预防医学会. 中国脑膜炎球菌疫苗预防接种专家共识[J].中华预防医学杂志, 2019,53(2):141-145. [4] Zhang Y, Wei D, Guo X, et al. Burden of Neisseria meningitidis infections in China: a systematic review and meta-analysis[J]. J Glob Health, 2016, 6(2):020409. [5] 段静留, 温晔, 彭少丹, 等. A、C、Y、W135群脑膜炎奈瑟菌抗体血清体外杀菌试验方法优化[J]. 微生物学免疫学进展, 2018, 46(3):18-26. [6] Villena R, Safadi MAP, Valenzuela MT, et al. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines[J]. Hum Vaccin Immunother, 2018, 14(5):1042-1057. [7] Gasparini R, Panatto D, Bragazzi NL, et al. How the knowledge of interactions between Meningococcus and the human immune system has been used to prepare effective Neisseria meningitidis vaccines[J]. J Immunol Res, 2015, 2015:189153. [8] Dretler AW, Rouphael NG, Stephens DS.Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development[J]. Hum Vaccin Immunother,2018,14(5):1146-1160. [9] Shaker R, Fayad D, Dbaiboa G. Challenges and opportunities for meningococcal vaccination in the developing world[J]. Hum Vaccin Immunother, 2018, 14(5):1084-1097. [10] 戴德芳,李放军,夏昕,等.1951—2016年湖南省流行性脑脊髓膜炎流行病学特征及菌群变迁趋势分析[J].实用预防医学, 2017, 24(12):1440-1442. [11] Sáez-Llorens X, Beltran-Rodriguez J, Novoa Pizarro JM, et al. Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults[J]. Hum Vaccin Immunother, 2018,14(5):1161-1174. [12] Tommassen J, Arenas J. Biological functions of the secretome of Neisseria meningitidis[J]. Front Cell Infect Microbiol,2017, 7:256. [13] 邵祝军.流行性脑脊髓膜炎流行现状及防控形势[J]. 中华预防医学杂志, 2019, 53(2):129-132. [14] Bogaerts B, Winand R, Fu Q, et al. Validation of a bioinformatics workflow for routine analysis of whole-genome sequencing data and relatedchallenges for pathogen typing in a European national reference center: Neisseria meningitidis as a proof-of-concept[J]. Front Microbiol, 2019, 10:362. [15] Guo Q, Mustapha MM, Chen M, et al. Evolution of sequence type 4821 clonal complex meningococcal strains in China from prequinolone to quinolone era, 1972-2013[J]. Emerg Infect Dis, 2018, 24(4):683-690. [16] Vuocolo S, Balmer P, Gruber WC, et al. Vaccination strategies for the prevention of meningococcal disease[J]. Hum Vaccin Immunother, 2018, 14(5):1203-1215.
2019, Vol. 26 
